Aging demographics and high cardiovascular burden underpin continued growth
As telehealth usage rises and weight-loss protocols integrate GLP-1s, off-label adoption has grown rapidly, reshaping demand across the USA, UK, and select European regions
Heres what the clinical data shows: Most Common: Nausea (affecting 15-44% of users), diarrhea (10-30%), vomiting (7-25%), and constipation (6-24%) Severity: 98.1% of gastrointestinal side effects are mild or moderate, with 99.5% being non-serious Duration: Median duration is 8 days for nausea, 3 days for diarrhea, and 2 days for vomiting Timing: Most side effects occur during initial weeks and dose escalation, declining over time Discontinuation: Only 4.3-10% of users discontinue therapy due to side effects Serious Events: Rare, with no increased risk of pancreatitis or malignancy in clinical trials Management: Slow dose titration, dietary modifications, and hydration significantly reduce symptoms Important Note: Weight loss is NOT caused by side effects
Any persistent abdominal pain, severe vomiting, or other concerning symptoms should be reported to your provider immediately
Drink water between meals rather than with food to avoid premature fullness